Celleste Bio

**Product and the concrete problem it solves.** Celleste Bio is tackling a narrow but consequential bottleneck in the chocolate supply chain: cocoa butter is not a decorative ingredient but the fat that gives chocolate its characteristic snap, shine, melting behavior, texture, and mouthfeel. The company says cocoa butter makes up about one-third of standard chocolate and is the most resource-intensive cocoa component to produce. Conventional supply depends heavily on cocoa trees concentrated in specific geographies, particularly West Africa, where climate disruption, disease, ageing plantations, deforestation, and competition for land have created volatile yields and prices. Celleste’s product is a real cocoa ingredient, not a cocoa-flavored substitute. Its lead output is chocolate-grade cocoa butter, with cocoa powder as a second product line, designed as a drop-in ingredient for chocolate manufacturers and ingredient companies. That matters commercially because a drop-in ingredient can fit existing recipes, tempering processes, factories, and quality standards rather than forcing a consumer brand to educate customers about a new category. The company is therefore selling supply-chain optionality and formulation continuity to industrial buyers, while preserving the taste and physical behavior that make chocolate difficult to reformulate.

**Core technology and how it works.** Celleste uses plant cell suspension culture as a controlled manufacturing platform. The process starts with naturally occurring cells taken from a small number of cocoa beans; public company and investor materials state that the cells are grown in a controlled environment with water and nutrients, without artificial genetic modification or manipulation. FoodNavigator describes the practical workflow as opening a cocoa bean, allowing cells to grow in a Petri dish, then fermenting the cells with water, sugar, and vitamins so biomass develops before it is harvested and processed into cocoa butter. The company’s model is analogous to a plant-derived biofactory: it reproduces the biological production of cocoa ingredients without waiting for a tree to mature, without relying on a particular growing region, and without harvesting a new pod for every production cycle. Celleste also combines biotechnology and agtech with AI computational modeling. The AI layer is intended to help characterize cocoa-cell behavior and tailor product properties such as melting temperature, sweetness, and flavor profile, while the wet-lab process provides the material that must ultimately meet chocolate-manufacturing specifications. The company describes its platform as patented, but no patent numbers, claims, jurisdictions, or freedom-to-operate analysis are publicly disclosed in the sources reviewed.

**Market, customers, and go-to-market.** Celleste is pursuing a business-to-business ingredient strategy aimed at chocolate manufacturers and specialty-ingredient companies. The initial buyer is not the end consumer but a manufacturer that needs reliable cocoa butter with conventional functionality, traceability, and the potential for specification control. The company’s website presents two product lines from one material source: a commodity-style chocolate-grade cocoa butter and powder line, plus tailored products with adjustable sweetness, melting temperature, and fine flavors. This creates two possible routes to market. A standard drop-in ingredient can compete on supply continuity, quality consistency, and eventual economics, while customized ingredients can help a manufacturer launch differentiated products without changing its core chocolate process. Mondelēz International is both a strategic partner and investor, giving Celleste access to a technically sophisticated confectionery organization and a potential route for product qualification. In April 2026, Mondelēz used Celleste’s cultured cocoa butter to make nearly a dozen milk-chocolate bars that met the company’s stated integrity and consumption standards. That is a meaningful customer-development milestone, but it is not a commercial launch or purchase commitment. Celleste is still moving from laboratory work into a 1,000-liter pilot facility, so the go-to-market remains dependent on regulatory approval, costed production, partner qualification, and reliable volume delivery.

**Traction, funding, and third-party validation.** Celleste was established in 2022 and announced a $4.5 million seed financing in 2024 led by Supply Change Capital, with participation from Mondelēz’s SnackFutures Ventures, Consensus Business Group, Trendlines, Barrel Ventures, and Regba Agriculture. A later company announcement stated that Celleste had raised $5.6 million in total, including non-dilutive grants. The Israel Innovation Authority lists Celleste Bio Ltd as an Israeli agritech company established in 2022, with 15 employees, R&D-stage status, and participation in its R&D and Startup Fund programs. Trendlines, the company’s incubator and early investor, reported in October 2025 that Celleste had produced the world’s first chocolate-grade cocoa butter using plant cell culture and was developing a pilot facility. In April 2026, Celleste and Mondelēz announced the first milk-chocolate bars made with Celleste’s cultured cocoa butter; independent FoodNavigator coverage described the process, the nearly dozen-bar pilot, the claimed sensory equivalence, the 1,000-liter pilot scale, and a market-readiness target of 2027. These are unusually concrete validation signals for an early food-biotechnology company: a strategic food manufacturer has tested the ingredient in finished products, a government innovation agency records the company and its R&D support, and an investor-backed pilot is being built. The boundaries are equally important. No public source reviewed here verifies recurring revenue, commercial shipments, independent lifecycle analysis, regulatory approval, audited production cost, or a signed long-term offtake agreement.

**Founders and team background.** Celleste’s founding team combines plant-cell biology, agrifood commercialization, and scientific advisory depth. Hanne Volpin, PhD, is identified as co-founder and chief technology officer; Trendlines describes her as a cellular-biology entrepreneur, while the company’s team page presents her as a specialist in cell biology, plant genetics, and computational modeling. The original founding group also included Orna Harel, Avishai Levy, and Daphna Michaeli, PhD, whose backgrounds are described in Trendlines and Food Business News as spanning cellular biology and agrifood. Michal Beressi Golomb is the current chief executive; company materials and industry coverage present her as the commercial leader responsible for translating the platform into a customer-ready cocoa ingredient, and the 2026 product announcement quotes her on the supply-chain mission. The wider team includes plant-cell, metabolism, data-science, and business specialists. Celleste’s advisory and board network includes Ian Noble, identified as a Mondelēz R&D executive, and Trendlines Agrifood leadership, creating a bridge between laboratory development and industrial chocolate requirements. The team is credible for early R&D and customer discovery, and the Israel Innovation Authority’s 15-employee figure indicates a real operating organization rather than a paper project. However, public disclosure does not establish the depth of the company’s manufacturing engineering, quality systems, regulatory affairs, or commercial procurement capacity. Those functions become critical as Celleste moves from a controlled experiment to food-ingredient production.

**Competitive dynamics.** Celleste occupies an unusual position because it is pursuing the cocoa-butter component that other cocoa-technology startups have not publicly demonstrated at the same level. California Cultured and Kokomodo are pursuing cell-cultured cocoa ingredients, especially cocoa powder, and could expand toward overlapping products. C16 Biosciences uses fermentation to produce a cocoa-butter alternative from yeast-derived oils, competing for the same manufacturer need even though its material and process differ. Planet A Foods develops cocoa-free chocolate from alternative raw materials and competes for brands willing to reformulate the finished product rather than secure real cocoa. Traditional cocoa processors and large commodity suppliers remain the practical incumbent: they have established farms, trading relationships, certification systems, factories, and customer contracts, and they benefit if cocoa prices or supply volatility normalize. Celleste’s claimed edge is a combination of authentic cocoa chemistry, a very small biological starting material, controlled production independent of geography, and a drop-in format that lowers switching friction. The company also claims it can use AI to tailor material properties instead of selling only a standardized commodity. None of that is a durable moat yet. Competitors can improve their own cell lines or fermentation economics, established suppliers can invest in alternatives, and a chocolate manufacturer may prefer a cheaper reformulation over a novel ingredient. Defensibility will depend on cell-line performance, process know-how, patents, food-grade consistency, regulatory acceptance, yield, and cost per kilogram at scale.

**Defense, security, and resilience dual-use relevance.** Celleste is not a defense contractor, and the public record does not identify a military customer, classified program, defense grant, or operational security deployment. Its dual-use case is instead commercial food production plus strategic food-system resilience. The same controlled biological manufacturing capability that makes cocoa butter for consumer chocolate can, in principle, diversify the supply of a globally traded food ingredient away from a narrow set of climate-exposed agricultural regions. That supports resilience against crop disease, extreme weather, shipping disruption, trade restrictions, and geopolitical instability. The Israeli Innovation Authority classifies Celleste in agritech, agrifood, climate tech, chemistry and materials, and FoodTech, while the company and Trendlines explicitly frame the technology as a way to build a resilient and traceable cocoa supply. This is relevant to Claw & Talon’s food-security thesis at the level of distributed biomanufacturing and allied supply-chain capacity, not at the level of battlefield hardware. A future resilience application could include regional production of shelf-stable cocoa ingredients for emergency food manufacturing or strategic stockpiles, but no such program is disclosed. The correct score is therefore meaningful but bounded: Celleste’s core technology serves a real commercial market and can strengthen food-input resilience, while any defense or emergency-procurement pathway remains prospective and must not be presented as fielded capability.

**Growth stage, trajectory, and key diligence risks.** Celleste is early-stage and approaching a major scale-up inflection point. The company has moved from a 2022 founding and early seed financing through a first chocolate-grade cocoa-butter milestone, a strategic partnership with Mondelēz, a reported 15-person team, and construction or finalization of a 1,000-liter pilot facility. Its stated target is market-ready cultured cocoa butter by 2027, but FoodNavigator correctly notes that market readiness does not guarantee immediate acceptance and that no cell-based cocoa product had received pre-market approval in the reviewed jurisdictions. The key diligence points are: (1) production yield, purification, flavor, stability, and cost at pilot and commercial volumes; (2) whether the sensory and chemical equivalence claims survive independent testing across cocoa varieties and chocolate recipes; (3) the regulatory path in the United States, European Union, United Kingdom, and Israel; (4) the scope and enforceability of the company’s patent portfolio and its freedom to operate; (5) construction, commissioning, and utilization of the pilot facility; (6) conversion of Mondelēz and other evaluations into repeat commercial orders; and (7) consumer and retailer acceptance of cell-cultured cocoa. There is also a strategic risk in the problem itself: cocoa prices and shortages can normalize, reducing urgency before Celleste reaches cost parity. The upside is a differentiated Israeli bioeconomy platform that can make a climate-exposed ingredient more geographically flexible. The bear case is that the biology works in the lab but cannot compete with conventional agriculture or alternative fats at food scale. This is a strategic diligence assessment, not an investment recommendation.